Radium‐223 in Asian patients with castration‐resistant prostate cancer with symptomatic bone metastases: A single‐arm phase 3 study-Reference-Cited by-同舟云学术

Radium‐223 in Asian patients with castration‐resistant prostate cancer with symptomatic bone metastases: A single‐arm phase 3 study

Published:2020-10-13 Issue:6 Volume:17 Page:462-470
ISSN:1743-7555
Container-title:Asia-Pacific Journal of Clinical Oncology
language:en
Short-container-title:Asia‐Pac J Clin Oncol

Author:

Zhou Tie¹^ORCID,Zhou Fangjian²,Guo Jianming³,Shi Hongcheng³,Yao Xudong⁴,Guo Hongqian⁵,Yuan Jian⁶,Tian Ye⁷,Zhang Xiaodong⁸,Wang Shuxia⁹,Jiang Yongguang¹⁰,Zou Qing¹¹,Zhou Daqing¹¹,Li Hanzhong¹²,Li Fang¹²,Lee Jae Lyun¹³^ORCID,Chen Chung‐Hsin¹⁴,Park Se Hoon¹⁵,Ng Quan Sing¹⁶,Ma Jianhui¹⁷,Zheng Rong¹⁷,Ding Qiang¹⁸,Liu Xingdang¹⁸,Li Rui¹⁹,Krissel Heiko²⁰,Wagner Volker J.²¹,Sun Yinghao¹

Affiliation:

1. Changhai Hospital Shanghai China

2. Sun Yat‐Sen University Cancer Center Guangzhou China

3. Shanghai Zhongshan Hospital Fudan University Shanghai China

4. Shanghai Tenth People's Hospital Shanghai China

5. Nanjing Drum Tower Hospital Nanjing China

6. The First Affiliated Hospital of Guangzhou Medical University Hospital Guangzhou China

7. Beijing Friendship Hospital of Capital Medical University Hospital Beijing China

8. Beijing Chaoyang Hospital of Capital Medical University Beijing China

9. Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences Guangzhou China

10. Beijing An Zhen Hospital of Capital Medical University Hospital Beijing China

11. Jiangsu Cancer Hospital Nanjing China

12. Peking Union Medical College Hospital Beijing China

13. Asan Medical Center University of Ulsan College of Medicine Seoul Korea

14. National Taiwan University Hospital Taipei Taiwan

15. Sungkyunkwan University Samsung Medical Center Seoul Korea

16. National Cancer Centre Singapore Singapore

17. National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

18. Fudan University Huashan Hospital Shanghai China

19. Bayer HealthCare Pharmaceuticals Inc. Whippany NJ USA

20. Bayer AG Berlin Germany

21. Bayer Consumer Care AG Basel Switzerland

Publisher

Wiley

Subject

Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajco.13479

Reference30 articles.

1. FerlayJ SoerjomataramI ErvikM et al. GLOBOCAN 2012 v1.0: Cancer Incidence and Mortality Worldwide. IARC CancerBase No. 11.2013.http://globocan.iarc.fr. Accessed October 30 2019.

2. GLOBOCAN.2018.http://gco.iarc.fr/today/data/factsheets/cancers/27-Prostate-fact_sheet.pdf. Accessed October 30 2019.

3. Global Incidence and Mortality for Prostate Cancer: Analysis of Temporal Patterns and Trends in 36 Countries

4. Prostate cancer in Asia: A collaborative report;Chen R;J Urol,2014

5. Epidemiology of prostate cancer in the Asia-Pacific region

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real‐world safety and effectiveness of radium‐223 in patients with metastatic castration‐resistant prostate cancer: Interim analyses of the prospective, observational RAPIT study;International Journal of Cancer;2024-06-26

2. Cinobufotalin Capsule Combined with Zoledronic Acid in the Treatment of Pain Symptoms and Clinical Efficacy in Prostate Cancer Patients with Bone Metastases: A Retrospective Study;Archivos Españoles de Urología;2024

3. Enzalutamide Prior to Radium-223 Is Associated with Better Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Compared to Abiraterone—A Retrospective Study;Cancers;2023-07-06

4. Tailoring radiotherapies and nanotechnology for targeted treatment of solid tumors;Coordination Chemistry Reviews;2022-12

5. Efficacy and Safety of Radium-223 for Castration-resistant Prostate Cancer With Bone Metastasis Before and After Docetaxel;Anticancer Research;2022-10